Koers Enzolytics Inc. Other OTC
Aandelen
ENZC
US2941121079
Biotechnologie & Medisch Onderzoek
Omzet 2009 | 0,01 0,01 | Omzet 2010 | 0,04 0,03 | Marktkapitalisatie | 7,45 mln. 6,97 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2009 | - 0 | Nettowinst (verlies) 2010 | -7 mln. -6,55 mln. | EV/omzet 2009 | 325.315.067 x |
Nettoschuld 2009 | 924K 864K | Nettoschuld 2010 | 328K 306K | EV/omzet 2010 | 210.445.953 x |
K/w-verhouding 2009 * |
-
| K/w-verhouding 2010 |
-0,29
x | Werknemers | - |
Dividendrendement 2009 * |
-
| Dividendrendement 2010 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 16-06-17 |
Joseph Cotropia
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gaurav Chandra
BRD | Director/Board Member | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 16-06-17 |
Joseph Cotropia
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gaurav Chandra
BRD | Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |